Hydrus与iStent inject微创青光眼手术植入物联合白内障手术的长期疗效比较
基于Fight Glaucoma Blindness登记处的回顾性研究,比较超声乳化联合Hydrus微支架(phaco-Hydrus)与联合iStent inject(phaco-iStent)的长期效果。在48个月时,两组达到主要终点(眼压下降≥20%且眼压≤21 mmHg或用药减少≥1种)的比例无显著差异(总体队列41.2% vs 43.0%,p=0.81;匹配队列44.1% vs 43.2%,p=0.99)。超过40%的眼维持主要成功终点且无需二次青光眼手术。
要点
- 48个月时phaco-Hydrus与phaco-iStent的手术成功率无显著差异(总体队列41.2% vs 43.0%,p=0.81)。
- 匹配队列中成功率同样无显著差异(44.1% vs 43.2%,p=0.99)。
- 两组眼压下降程度、用药减少及调整后次要结局均无显著差异,不良事件和二次手术发生率相似。
核心结论
- 48个月时phaco-Hydrus与phaco-iStent两组手术成功率无显著差异。
- 超过40%的眼维持主要成功终点(眼压下降≥20%且眼压≤21 mmHg或用药减少≥1种)且无需二次青光眼手术。
研究设计与样本
- 回顾性研究,纳入Fight Glaucoma Blindness登记处中接受phaco-Hydrus或phaco-iStent且随访至少48个月的眼。
- 总体队列431眼(phaco-Hydrus 98眼,phaco-iStent 331眼),匹配队列177眼(phaco-Hydrus 59眼,phaco-iStent 118眼)。
- 采用倾向性评分匹配基线协变量。
- 预设主要终点为48个月时眼压下降≥20%且眼压≤21 mmHg或较基线用药减少≥1种,无术前洗脱。
主要发现
- 总体队列48个月主要终点达成率:phaco-Hydrus组41.2% vs phaco-iStent组43.0%,p=0.81,无显著差异。
- 匹配队列48个月主要终点达成率:phaco-Hydrus组44.1% vs phaco-iStent组43.2%,p=0.99,无显著差异。
- 两组眼压下降程度、用药减少及调整后次要结局在总体和匹配队列中均无显著差异。
- 两组不良事件和二次手术发生率相似。
关键数值与推荐
- 主要终点:48个月时眼压下降≥20%且眼压≤21 mmHg或较基线用药减少≥1种,无术前洗脱。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To compare the long-term effectiveness of combined phacoemulsification and Hydrus microstent (phaco-Hydrus) versus iStent inject (phaco-iStent) using microinvasive glaucoma surgery-specific surgical success definitions in a large observational cohort. METHODS: Retrospective study of eyes in the Fight Glaucoma Blindness registry that underwent phaco-Hydrus or phaco-iStent with a minimum of 48 months follow-up. The prespecified primary endpoint was ≥20% intraocular pressure (IOP) decrease and IOP ≤21 mm Hg or ≥1 medication reduction versus baseline at 48 months with no preoperative washout. Propensity score matching of baseline covariates was used to examine outcomes in a subcohort (matched cohort). RESULTS: 431 eyes (98 phaco-Hydrus: 331 phaco-iStent) were included in the overall cohort and 177 eyes (59 phaco-Hydrus: 118 phaco-iStent) in the matched cohort. There was no significant difference in the rate of surgical success between each group in achieving the primary endpoint at 48 months (adjusted overall cohort, 41.2% vs 43.0% in phaco-Hydrus vs phaco-iStent respectively, p=0.81; matched cohort, 44.1% vs 43.2%, p=0.99). There was no significant difference in degree of IOP reduction, medication reduction and adjusted secondary outcomes between the phaco-Hydrus and phaco-iStent groups in both overall and matched cohorts. The incidence of adverse events and secondary procedures was similar between both groups. CONCLUSION: There was no significant difference in surgical success between phaco-Hydrus and phaco-iStent groups at 48 months. Over 40% of eyes maintained the primary success endpoint of ≥20% IOP decrease and IOP ≤21 mm Hg or ≥1 medication reduction versus baseline without the need for secondary glaucoma surgery.
引用
- Tan JCK, Clement C, Healey P, et al. Long-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery. Br J Ophthalmol. 2025. PMID: 40830030. doi:10.1136/bjo-2025-327359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。